To evaluate the clinical efficacy and feasibility application of a human urinary protease inhibitor (Ulinastatin, UTI) for the patients with acute severe traumatic craniocerebral injury. 90 cases with acute severe traumatic craniocerebral injury were randomly divided into the Ulinastatin treatment group (45 cases) and the control group (45 cases), the control group received piracetam treatment. Ulinastatin conventional therapy in the treatment group based on the intravenous injection of Ulinastatin 200000U, 2 times per day, 12 days a cycle, at the same time, piracetam treatment is based on the intravenous drip piracetam 20ml:4g, 2times/d, 12 days a cycle. The clinical effects was assessed with the GCS and MMSE score sheet at the 12th day and the GOS score sheet at 6 months after craniocerebral injury. Record the side effects and complications such as incidences of alimentary tract hemorrhage, liver damage and renal function injury. Comparing the treatment group with the control group, GCS score and MMSE score had significant difference (P<0.05), 6 months GOS score of the neurological function recovery in the treatment group was significantly better than that in the control group(P<0.05). Ulinastatin not only appears the effective treatment and promotes the neurological function recovery, but also reduces the risk of death for the patients with severe traumatic craniocerebral injury. Ulinastatin is safe and reliable treating on the patients with acute severe traumatic craniocerebral injury